158 related articles for article (PubMed ID: 30543563)
1. Protein kinase C-α is upregulated by IMP1 in melanoma and is linked to poor survival.
Mahapatra L; Andruska N; Mao C; Gruber SB; Johnson TM; Fullen DR; Raskin L; Shapiro DJ
Melanoma Res; 2019 Oct; 29(5):539-543. PubMed ID: 30543563
[TBL] [Abstract][Full Text] [Related]
2. Targeting insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in metastatic melanoma to increase efficacy of BRAF
Kim T; Havighurst T; Kim K; Albertini M; Xu YG; Spiegelman VS
Mol Carcinog; 2018 May; 57(5):678-683. PubMed ID: 29369405
[TBL] [Abstract][Full Text] [Related]
3. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
[TBL] [Abstract][Full Text] [Related]
4. Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2.
Xu S; Yang Z; Zhang J; Jiang Y; Chen Y; Li H; Liu X; Xu D; Chen Y; Yang Y; Zhang Y; Li D; Xia J
DNA Cell Biol; 2015 Jan; 34(1):69-77. PubMed ID: 25343173
[TBL] [Abstract][Full Text] [Related]
5. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
6. ERK/MAPK Signaling Drives Overexpression of the Rac-GEF, PREX1, in BRAF- and NRAS-Mutant Melanoma.
Ryan MB; Finn AJ; Pedone KH; Thomas NE; Der CJ; Cox AD
Mol Cancer Res; 2016 Oct; 14(10):1009-1018. PubMed ID: 27418645
[TBL] [Abstract][Full Text] [Related]
7. miR-146a promotes the initiation and progression of melanoma by activating Notch signaling.
Forloni M; Dogra SK; Dong Y; Conte D; Ou J; Zhu LJ; Deng A; Mahalingam M; Green MR; Wajapeyee N
Elife; 2014 Feb; 3():e01460. PubMed ID: 24550252
[TBL] [Abstract][Full Text] [Related]
8. E3 ubiquitin ligase PARK2, an inhibitor of melanoma cell growth, is repressed by the oncogenic ERK1/2-ELK1 transcriptional axis.
Montagnani V; Maresca L; Apollo A; Pepe S; Carr RM; Fernandez-Zapico ME; Stecca B
J Biol Chem; 2020 Nov; 295(47):16058-16071. PubMed ID: 32938713
[TBL] [Abstract][Full Text] [Related]
9. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M
Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
[TBL] [Abstract][Full Text] [Related]
10. AURKA Overexpression Is Driven by FOXM1 and MAPK/ERK Activation in Melanoma Cells Harboring BRAF or NRAS Mutations: Impact on Melanoma Prognosis and Therapy.
Puig-Butille JA; Vinyals A; Ferreres JR; Aguilera P; Cabré E; Tell-Martí G; Marcoval J; Mateo F; Palomero L; Badenas C; Piulats JM; Malvehy J; Pujana MA; Puig S; Fabra À
J Invest Dermatol; 2017 Jun; 137(6):1297-1310. PubMed ID: 28188776
[TBL] [Abstract][Full Text] [Related]
11. miR-524-5p suppresses the growth of oncogenic BRAF melanoma by targeting BRAF and ERK2.
Liu SM; Lu J; Lee HC; Chung FH; Ma N
Oncotarget; 2014 Oct; 5(19):9444-59. PubMed ID: 25275294
[TBL] [Abstract][Full Text] [Related]
12. The rise of T-type channels in melanoma progression and chemotherapeutic resistance.
Alza L; Visa A; Herreros J; Cantí C
Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188364. PubMed ID: 32275934
[TBL] [Abstract][Full Text] [Related]
13. A Novel IMP1 Inhibitor, BTYNB, Targets c-Myc and Inhibits Melanoma and Ovarian Cancer Cell Proliferation.
Mahapatra L; Andruska N; Mao C; Le J; Shapiro DJ
Transl Oncol; 2017 Oct; 10(5):818-827. PubMed ID: 28846937
[TBL] [Abstract][Full Text] [Related]
14. MAP kinase pathway gene copy alterations in NRAS/BRAF wild-type advanced melanoma.
Orouji E; Orouji A; Gaiser T; Larribère L; Gebhardt C; Utikal J
Int J Cancer; 2016 May; 138(9):2257-62. PubMed ID: 26684394
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
Trunzer K; Pavlick AC; Schuchter L; Gonzalez R; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Kim KB; Weber JS; Hersey P; Long GV; Lawrence D; Ott PA; Amaravadi RK; Lewis KD; Puzanov I; Lo RS; Koehler A; Kockx M; Spleiss O; Schell-Steven A; Gilbert HN; Cockey L; Bollag G; Lee RJ; Joe AK; Sosman JA; Ribas A
J Clin Oncol; 2013 May; 31(14):1767-74. PubMed ID: 23569304
[TBL] [Abstract][Full Text] [Related]
16. TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation.
Vallarelli AF; Rachakonda PS; André J; Heidenreich B; Riffaud L; Bensussan A; Kumar R; Dumaz N
Oncotarget; 2016 Aug; 7(33):53127-53136. PubMed ID: 27449293
[TBL] [Abstract][Full Text] [Related]
17. The plasma membrane Ca
Hegedũs L; Garay T; Molnár E; Varga K; Bilecz Á; Török S; Padányi R; Pászty K; Wolf M; Grusch M; Kállay E; Döme B; Berger W; Hegedũs B; Enyedi A
Int J Cancer; 2017 Jun; 140(12):2758-2770. PubMed ID: 27813079
[TBL] [Abstract][Full Text] [Related]
18. [Biological role and prognostic significance of genetic alterations in human malignant melanomas].
Vízkeleti L
Magy Onkol; 2015 Sep; 59(3):268-72. PubMed ID: 26339916
[TBL] [Abstract][Full Text] [Related]
19. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
[TBL] [Abstract][Full Text] [Related]
20. KIT Suppresses BRAF
Neiswender JV; Kortum RL; Bourque C; Kasheta M; Zon LI; Morrison DK; Ceol CJ
Cancer Res; 2017 Nov; 77(21):5820-5830. PubMed ID: 28947418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]